CY1119198T1 - ΣΤΑΘΕΡΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ PTHrP ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΗΣ - Google Patents

ΣΤΑΘΕΡΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ PTHrP ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΗΣ

Info

Publication number
CY1119198T1
CY1119198T1 CY20171100860T CY171100860T CY1119198T1 CY 1119198 T1 CY1119198 T1 CY 1119198T1 CY 20171100860 T CY20171100860 T CY 20171100860T CY 171100860 T CY171100860 T CY 171100860T CY 1119198 T1 CY1119198 T1 CY 1119198T1
Authority
CY
Cyprus
Prior art keywords
pthrp
stable composition
composition including
stable
storage
Prior art date
Application number
CY20171100860T
Other languages
English (en)
Inventor
Michael J Dey
Nathalie Mondoly
Benedicte Rigaud
Bart Henderson
C Richard Lyttle
Original Assignee
Radius Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430237&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119198(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Health, Inc. filed Critical Radius Health, Inc.
Publication of CY1119198T1 publication Critical patent/CY1119198T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει σύνθεση σταθερή κατά την αποθήκευση, που περιέχει ανάλογο πρωτεΐνης που σχετίζεται με ορμόνη παραθυρεοειδούς (PTHrP) και μεθόδους χρήσης του αναλόγου PTHrP και των συνθέσεων PTHrP που περιγράφονται στο παρόν για θεραπεία οστεοπόρωσης, για αύξηση οστικής μάζας ή βελτίωση της ποιότητας οστού. Η σύνθεση είναι σταθερή κατά την αποθήκευση, σε αποστειρωμένη μορφή και γενικώς μπορεί να αποθηκεύεται σε θερμοκρασία δωματίου για τουλάχιστον αρκετές εβδομάδες ώστε να επιτρέπεται κατάλληλη παρεντερική χορήγηση σε ασθενείς ανθρώπους.
CY20171100860T 2006-10-03 2017-08-10 ΣΤΑΘΕΡΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ PTHrP ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΗΣ CY1119198T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896006P 2006-10-03 2006-10-03
EP07870768.4A EP2073789B8 (en) 2006-10-03 2007-10-03 A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof

Publications (1)

Publication Number Publication Date
CY1119198T1 true CY1119198T1 (el) 2018-02-14

Family

ID=39430237

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100860T CY1119198T1 (el) 2006-10-03 2017-08-10 ΣΤΑΘΕΡΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ PTHrP ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΗΣ

Country Status (28)

Country Link
US (1) US8148333B2 (el)
EP (2) EP2073789B8 (el)
JP (1) JP5375611B2 (el)
KR (4) KR101512377B1 (el)
CN (2) CN102274492B (el)
AU (1) AU2007322334B2 (el)
BR (2) BRPI0722428A2 (el)
CA (1) CA2664734C (el)
CY (1) CY1119198T1 (el)
DK (2) DK2073789T3 (el)
ES (2) ES2637283T3 (el)
FR (1) FR23C1024I2 (el)
HK (1) HK1214181A1 (el)
HR (1) HRP20171217T1 (el)
IL (1) IL197926A (el)
LT (1) LT2957278T (el)
MX (1) MX2009003569A (el)
NL (1) NL301235I2 (el)
NO (1) NO344885B1 (el)
NZ (1) NZ576682A (el)
PL (1) PL2957278T3 (el)
PT (2) PT2957278T (el)
RS (1) RS56164B1 (el)
RU (1) RU2506070C2 (el)
SG (1) SG175580A1 (el)
SI (1) SI2957278T1 (el)
UA (1) UA98776C2 (el)
WO (1) WO2008063279A2 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148333B2 (en) 2006-10-03 2012-04-03 Radius Health, Inc. Stable composition comprising a PTHrP analogue
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
EP2472328B1 (en) 2010-12-31 2013-06-19 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2472329B1 (en) 2010-12-31 2013-06-05 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
SG194570A1 (en) 2011-04-22 2013-12-30 Radius Health Inc Method of drug delivery for pth, pthrp and related peptides
KR101787956B1 (ko) * 2011-06-07 2017-10-18 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
AU2012345768B2 (en) * 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
CN108024540B (zh) 2015-04-29 2021-09-17 雷迪厄斯制药公司 用于治疗癌症的方法
WO2017007777A2 (en) * 2015-07-06 2017-01-12 Zhengxin Dong NOVEL FORMULATIONS OF PTHrP ANALOGUE
KR101982103B1 (ko) 2015-08-31 2019-05-27 롬 앤드 하스 일렉트로닉 머트어리얼즈 엘엘씨 오버코팅된 포토레지스트와 함께 사용하기 위한 코팅 조성물
SI3359241T1 (sl) * 2015-10-09 2021-11-30 Radius Health, Inc. Formulacije PTHRP-analogov, transdermalni obliži le-teh in uporabe le-teh
WO2017184355A1 (en) 2016-04-18 2017-10-26 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
CA3027563A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
MX2019006189A (es) * 2016-11-30 2019-11-18 Purdue Research Foundation Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
CN1204262A (zh) * 1995-10-17 1999-01-06 曼海姆泊灵格股份公司 稳定的含甲状旁腺激素的药物给药剂型
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
KR100679778B1 (ko) 1997-09-09 2007-02-07 에프. 호프만-라 로슈 아게 PTHrP 유사체를 사용하는 골절 치료법
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2003105772A2 (en) * 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
WO2004060386A1 (en) 2002-11-01 2004-07-22 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
EP1750756A2 (en) * 2004-05-10 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US8148333B2 (en) 2006-10-03 2012-04-03 Radius Health, Inc. Stable composition comprising a PTHrP analogue

Also Published As

Publication number Publication date
ES2739459T3 (es) 2020-01-31
PT2073789T (pt) 2019-07-31
SG175580A1 (en) 2011-11-28
CN101578093A (zh) 2009-11-11
UA98776C2 (ru) 2012-06-25
RU2009116531A (ru) 2010-11-10
LT2957278T (lt) 2017-09-11
RS56164B1 (sr) 2017-11-30
PL2957278T3 (pl) 2017-10-31
BRPI0719821B1 (pt) 2020-04-14
JP5375611B2 (ja) 2013-12-25
NO20091545L (no) 2009-05-27
US20100029556A1 (en) 2010-02-04
WO2008063279A2 (en) 2008-05-29
MX2009003569A (es) 2009-08-25
EP2073789B8 (en) 2022-09-14
NL301235I2 (nl) 2023-08-31
BRPI0719821A2 (pt) 2013-05-07
CA2664734C (en) 2023-08-01
PT2957278T (pt) 2017-08-23
NO344885B1 (no) 2020-06-15
JP2010505835A (ja) 2010-02-25
EP2073789B1 (en) 2019-05-22
DK2073789T3 (da) 2019-08-05
NZ576682A (en) 2012-08-31
FR23C1024I1 (fr) 2023-07-21
KR20150020289A (ko) 2015-02-25
EP2073789A2 (en) 2009-07-01
AU2007322334B2 (en) 2011-12-22
KR20170067906A (ko) 2017-06-16
BRPI0719821B8 (pt) 2021-05-25
RU2506070C2 (ru) 2014-02-10
WO2008063279A9 (en) 2008-07-10
CN102274492A (zh) 2011-12-14
US8148333B2 (en) 2012-04-03
FR23C1024I2 (fr) 2024-06-14
EP2957278B1 (en) 2017-05-17
ES2637283T3 (es) 2017-10-11
WO2008063279A3 (en) 2009-06-25
SI2957278T1 (sl) 2017-09-29
AU2007322334A1 (en) 2008-05-29
HK1214181A1 (zh) 2016-07-22
IL197926A (en) 2014-08-31
DK2957278T3 (en) 2017-07-31
CN101578093B (zh) 2011-09-14
KR20180117738A (ko) 2018-10-29
IL197926A0 (en) 2011-08-01
CN102274492B (zh) 2014-11-26
HRP20171217T1 (hr) 2017-10-20
KR101512377B1 (ko) 2015-04-28
EP2957278A1 (en) 2015-12-23
KR20090083350A (ko) 2009-08-03
CA2664734A1 (en) 2008-05-29
BRPI0722428A2 (pt) 2013-11-26

Similar Documents

Publication Publication Date Title
CY1119198T1 (el) ΣΤΑΘΕΡΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ PTHrP ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΗΣ
CY1121461T1 (el) Συνθεσεις που περιλαμβανουν δυσδιαλυτους στο νερο φαρμακευτικους παραγοντες και αντιμικροβιακους παραγοντες
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1122681T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
SG162788A1 (en) Self-buffering protein formulations
CY1119853T1 (el) Χρηση στρωματικων βλαστοκυτταρων λαμβανομενων απο ιστο αδιποζης στην θεραπεια συριγγιου
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
MX2012003408A (es) Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2.
CY1113108T1 (el) Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1108421T1 (el) Η χρηση σκευασματων μελοξικαμης στην κτηνιατρικη
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CY1112284T1 (el) Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων
HK1113970A1 (en) Formulations for injection of catecholic butanes, including ndga compounds, into animals
ES2249490T3 (es) Articulos quirurgicos.
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
BRPI0519070A2 (pt) composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
EA201270116A1 (ru) Применение лекарственной формы для наружного нанесения, содержащей хитозан
EP2392322A3 (en) Dosing regimes for trans-clomiphene
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
CY1113726T1 (el) Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten